Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Pitavastatin Tablets in 1mg, 2mg, and 4mg strengths.
The product is an AB-rated, generic equivalent to the brand product, LIVALO (pitavastatin) tablets.
Sawai USA, Inc, a company of Sawai Group Holdings Co., Ltd. (Sawai), has the ANDA for Pitavastatin tablets and it represents Sawai's first Paragraph IV product to be introduced in the United States. The company is distributing the product in the United States.
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
Emmaus Life Sciences names new chief executive officer
Sun Pharma finalises Taro acquisition
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Lutris Pharma names new director
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia